MarketPulse

NDA rejection

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Faces Class Action Over Relacorilant Trial Claims and FDA Disclosure Gaps

Lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug trials and FDA communications, covering October 2024-December 2025 investor purchases.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Alleges Corcept Misrepresented Relacorilant Clinical Data

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.
CORTsecurities fraudclass action lawsuit